Pescetto B, Gal J, Chamorey E, Dassonville O, Poissonnet G, Bozec A
Institut universitaire de la Face et du Cou, 31, avenue de Valombrose, 06103 Nice, France.
Département de biostatistiques, centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice, France.
Eur Ann Otorhinolaryngol Head Neck Dis. 2018 Aug;135(4):249-253. doi: 10.1016/j.anorl.2018.05.004. Epub 2018 Jun 7.
To analyze oncologic and functional outcomes after supracricoid laryngectomy with cricohyoidoepiglottopexy (SCL-CHEP) in glottic carcinoma with anterior commissure (AC) involvement, to determine predictive factors, and to compare results with those reported for other therapeutic strategies.
A retrospective analysis included all patients who underwent SCL-CHEP for glottic squamous cell carcinoma with anterior commissure involvement in our institution, between 2000 and 2014. Swallowing function was evaluated on the DOSS (Dysphagia Outcomes and Severity Scale).
Fifty-three patients were included. Three-year overall, cause-specific and recurrence-free survival rates were 86, 95 and 80%, respectively. There were 5 cases of local recurrence (9%), all treated by total laryngectomy. Smoking was the only predictive factor of recurrence-free survival (P=0.02). Mean DOSS score was 5.5±0.9. DOSS scores≥6 (normal oral feeding) were recovered by 59% of patients. T-stage≥2 was the only predictive factor for DOSS score (P=0.04).
In glottic carcinoma with anterior commissure involvement, SCL with CHEP provided a local control rate of more than 90%, which is higher than reported with endoscopic surgery or external radiotherapy. However, contrary to LSC, salvage of local recurrence can often be obtained by conservative treatments after endoscopic surgery. Therefore, total-laryngectomy-free survival rates after SCL-CHEP and endoscopic surgery are finally comparable.
分析环状软骨上喉部分切除术联合环状软骨舌骨会厌固定术(SCL-CHEP)治疗累及前联合(AC)的声门癌的肿瘤学及功能学结局,确定预测因素,并将结果与其他治疗策略的报告结果进行比较。
一项回顾性分析纳入了2000年至2014年间在我院接受SCL-CHEP治疗累及前联合的声门鳞状细胞癌的所有患者。吞咽功能采用吞咽困难结局与严重程度量表(DOSS)进行评估。
共纳入53例患者。3年总生存率、病因特异性生存率和无复发生存率分别为86%、95%和80%。有5例局部复发(9%),均接受全喉切除术治疗。吸烟是无复发生存的唯一预测因素(P=0.02)。DOSS平均评分为5.5±0.9。59%的患者恢复至DOSS评分≥6(正常经口进食)。T分期≥2是DOSS评分的唯一预测因素(P=0.04)。
对于累及前联合的声门癌,SCL联合CHEP的局部控制率超过90%,高于内镜手术或外照射放疗的报告结果。然而,与全喉切除术不同,内镜手术后局部复发通常可通过保守治疗挽救。因此,SCL-CHEP和内镜手术后的无全喉切除生存率最终相当。